Prior Local Treatment Does Not Impact Survival Benefit of Enzalutamide/ADT in mHSPC
May 14th 2022Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
Upfront Olaparib/Abiraterone Achieves Significant rPFS Benefit in mCRPC
February 18th 2022A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.
Adding Ibrutinib Improves the Efficacy of Liso-Cel in R/R CLL
January 28th 2022Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.
COVID-19 Mortality Rates Linked to Active Disease, ICU Deferral in AML, ALL, and MDS
December 12th 2021Patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome had higher mortality rates after being diagnosed with COVID-19 than those with COVID-19 who did not have cancer.
pCR, EFS, Improved with Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib in TNBC
September 17th 2021Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.
DFS Benefit of Adjuvant Pembrolizumab Seen Across RCC Subgroups
September 14th 2021An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.
Checkpoint Blockade Response Linked With MSI-H/dMMR Prostate Cancer
September 11th 2021Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.